Executive readout · one minute
What the filings say
- 8-K earnings release · filed Nov 9, 2026
- Zymeworks raised 2026 revenue guidance to $337 million to $351 million and adjusted EBITDA guidance to $176 million to $190 million. Third-quarter revenue reached $256.5 million, primarily on a $250.0 million Ziihera milestone following first-line HER2-positive GEA approval.
- 10-Q report · filed Nov 9, 2026
- Zymeworks reported net income of $84.5 million for the nine months ended September 30, 2026 and expects existing cash plus a $250.0 million Jazz milestone payment received in October 2026 to fund operations for at least the next twelve months.
The audio replay and transcript follow the call.